Patient Involvement in HTA Processes – EFNA Recommendations

EFNA has today published a review the current state of play of Patient and Public Involvement (PPI) in Health Technology Assessment (HTA) across Europe.

Meaningful patient involvement in Health Technology Assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions.

Involving patient organisations in the process of patient involvement in Health Technology Assessment (HTA) practices is vital due to their unique understanding of the needs of a community as a whole. Patient organisations are intimately familiar with the experiences and perspectives of individuals living with specific health conditions, as well as the broader challenges faced by the community. Their input can provide valuable insights into the real-world impact of healthcare technologies, ensuring that HTA practices take into account the diverse needs and preferences of patients. By involving patient organisations, HTA processes can become more patient-centered, transparent, and responsive, ultimately leading to the development and adoption of health technologies that better meet the needs of the communities they serve.

Among other national research, this review draws on major European studies conducted by Health Technology Assessment International (HTAi), the EFPIA W.A.I.T. survey conducted by IQVIA and provides solutions via PPI in HTA processes to address the significant disparities in the rate of and time to availability of neurological therapeutics across Europe.

As a result of conducting this review EFNA calls for the following:

  • Support for the recommendations to overcome the barriers to PPI in Central and Eastern European Countries
  • Support for the recommendations of the HTAi October 2023 report for best practices for patient involvement in HTA processes
  • Consistent core essential requirements for patient involvement in HTA processes in all European countries to ensure timely processes with the most robust, evidence-based evaluation (Training and Government Mandates)
  • Members States and Patient Organisations to facilitate the capability and capacity of patient stakeholders to know about opportunities in HTA processes and how to get involved
  • Use of best-case study examples such as that shown in this report
  • Compliance with the EU Transparency Directive (European Commission, 1988 which sets a strict maximum time of 180 days for reaching a national P&R decision to expedite decision making

Click here to download the report

This report has been kindly supported by Pfizer